New York City Metropolitan Area, United States, February 2026 – Lauren Johnson has started her new position as CFO, External Innovation Finance at Johnson & Johnson. In this role, she will lead finance strategy supporting external innovation initiatives, strengthening the company’s ability to invest in and scale breakthrough healthcare solutions.
Prior to this appointment, Lauren served as Senior Director, Investor Relations at Johnson & Johnson, where she played a key role in engaging with the investment community and shaping financial communications at the enterprise level. Earlier, within Johnson & Johnson Innovative Medicine, she was Senior Finance Director, Portfolio, FP&A, and Business Operations, driving the annual long-range financial plan and ten-year outlook for the Innovative Medicine sector. She led global R&D budget oversight, portfolio analytics across the full pipeline, and managed a global team of approximately 35 professionals.
Her earlier leadership includes serving as Finance Director, CVM & PH Therapeutic Areas at Janssen R&D, providing financial stewardship for Cardiovascular, Metabolism, Retina, and Pulmonary Hypertension therapeutic areas. She also held multiple senior finance roles across supply chain acquisitions and divestitures, commercial finance, and global reporting, supporting significant transactions including the $2.8B sale of Advanced Sterilization Products and the $1B divestiture of Codman CNS.
Lauren began her career at Johnson & Johnson in financial analyst roles spanning IT, diagnostics, pharmaceuticals, and corporate functions, steadily building expertise in forecasting, P&L management, business transformation, and operational finance. She holds an MBA in Marketing and Strategy from New York University – Leonard N. Stern School of Business.
About Johnson & Johnson
Johnson & Johnson is a global healthcare innovator operating across Innovative Medicine and MedTech. With a mission grounded in advancing health for humanity, the company develops treatments and technologies that prevent, treat, and cure complex diseases while delivering smarter, less invasive, and more personalized healthcare solutions worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
